Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Announces Adjusted VersaFilm® Business Strategy, Next Steps for RIZAPORT® VersaFilm® Program

GlobeNewswire April 6, 2020

IIROC Trading Resumption - IGX

Canada NewsWire March 27, 2020

IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

GlobeNewswire March 27, 2020

IIROC Trading Halt - IGX

Canada NewsWire March 27, 2020

IntelGenx Reports Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire March 26, 2020

INTELGENX TO REPORT FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS ON MARCH 26; CONFERENCE CALL TO FOLLOW ON MARCH 27

GlobeNewswire March 23, 2020

IntelGenx Completes C$8.2 Million Equity Offering

GlobeNewswire February 11, 2020

IntelGenx Announces Pricing of Equity Offering

GlobeNewswire January 27, 2020

IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

GlobeNewswire January 15, 2020

IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

GlobeNewswire January 13, 2020

IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm(TM) Platform

GlobeNewswire January 9, 2020

IIROC Trading Resumption - IGX

Canada NewsWire December 20, 2019

IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

GlobeNewswire December 19, 2019

IIROC Trading Halt - IGX

Canada NewsWire December 19, 2019

IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

GlobeNewswire December 6, 2019

IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

GlobeNewswire December 3, 2019

IntelGenx Reports Third Quarter 2019 Financial Results

GlobeNewswire November 7, 2019

IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 - Conference Call to Follow

GlobeNewswire November 1, 2019

IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product

GlobeNewswire October 31, 2019

IntelGenx Announces FDA's Acceptance of Resubmitted RIZAPORT® New Drug Application

GlobeNewswire October 22, 2019